BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 36926326)

  • 1. Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials.
    Liu H; Luo SX; Jie J; Peng L; Wang S; Song L
    Front Immunol; 2023; 14():1115305. PubMed ID: 36926326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
    Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
    Front Immunol; 2021; 12():760737. PubMed ID: 34925331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
    Fujiwara Y; Horita N; Namkoong H; Galsky MD
    Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
    Zhao Z; Zhang W; Pang L; Zeng L; Liu S; Liu J
    Front Immunol; 2023; 14():1166299. PubMed ID: 37359551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
    Qin Q; Wang J; Wang H
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Xia H; Zhang W; Zhang Y; Shang X; Liu Y; Wang X
    Front Oncol; 2022; 12():978069. PubMed ID: 36330494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
    Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
    Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.
    Sharma A; Alexander G; Chu JH; Markopoulos A; Maloul G; Ayub MT; Fidler MJ; Okwuosa TM
    J Am Heart Assoc; 2024 May; 13(10):e032620. PubMed ID: 38761070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J
    Front Immunol; 2022; 13():908173. PubMed ID: 35880172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The entanglement of extracellular matrix molecules and immune checkpoint inhibitors in cancer: a systematic review of the literature.
    Fejza A; Carobolante G; Poletto E; Camicia L; Schinello G; Di Siena E; Ricci G; Mongiat M; Andreuzzi E
    Front Immunol; 2023; 14():1270981. PubMed ID: 37854588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis.
    Chen X; Zhang Z; Hou X; Zhang Y; Zhou T; Liu J; Lin Z; Fang W; Yang Y; Ma Y; Huang Y; Zhao H; Zhang L
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32863271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients.
    Xue C; Zheng S; Dong H; Lu X; Zhang X; Zhang J; Li J; Cui H
    Front Oncol; 2021; 11():627016. PubMed ID: 34513654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Shen J; Hou H; Liang B; Guo X; Chen L; Yang Y; Wang Y
    Front Immunol; 2023; 14():1155104. PubMed ID: 37153578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.